Efficacy of topical unoprostone treatment for nonarteritic anterior ischemic optic neuropathy

Efficacy of topical unoprostone treatment for nonarteritic anterior ischemic optic neuropathy - Topical unoprostone treatment for nonarteritic anterior ischemic optic neuropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002666

Enrollment

Registered

2009-12-01

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonarteritic anterior ischemic optic neuropathy

Interventions

Unoprostone 3 drops twice a day for the first month 2 drops twice a day after the first month until 1 year Control (Vitamine B12) 3 drops twice a day for the first month 2 drops twice a day after

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Aged 50 years or older 2) Duration of symptoms < 2 weeks 3) Visual loss or visual field defects consistent with optic neuropathy 4) Painless 5) Relative afferent pupillary defect 6) Optic disc edema

Exclusion criteria

Exclusion criteria: Arteritic ischemic optic neuropathy Glaucoma Optic neuritis Compressive optic neuropathy Leber hereditary optic neuropathy Toxic and nutritional optic neuropathy

Design outcomes

Primary

Measure	Time frame
Mean deviation of Humphrey field analyzer at 12 months	—

Secondary

Measure	Time frame
Mean deviation of Humphrey field analyzer at 6 months Visual acuity at 6, 12 months Goldmann perimetry at 12 months Ocular fundus at 6, 12 months Retinal nerve fiber layer thickness using optical coherence tomography at 6, 12 months	—

Countries

Japan

Contacts

Public ContactKeigo Shikishima

The Jikei University School of Medicine Department of Ophthalmology

shiki@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026